

Enterobacteriaceae – Clinical
Subgroups/Author(s)

ESBL Producing

Umair et al., 2019
Luxmi and Javed, 2018
Abrar et al., 2017
Rahman et al., 2016
Habeeb et al., 2014
Habeeb et al., 2013
Khan et al., 2010
Jabeen et al., 2010

RE Model for Subgroup

(T² = 0.0000, df = 7, Q = 98.67,
p < .0001; H² = 14.1, I² = 92.9%)

ACBL Producing

Younas et al., 2018
Jameel et al., 2014
Hassan et al., 2011

RE Model for Subgroup

(T² = 0.0090, df = 2, Q = 53.49,
p < .0001; H² = 26.7, I² = 96.3%)

Naive Isolates

Talpur et al., 2020
Qamar et al., 2019a
Ahmed et al., 2019
Sattar et al., 2019
Sana et al., 2019
Heinz et al., 2019
Ansari et al., 2018
J. Jamil et al., 2018
Humayun et al., 2018
Ain et al., 2018
B. Jamil et al., 2018
Alizai et al., 2018
Khan et al., 2017
Shabbir et al., 2017
Javed et al., 2016
Malik and Ahmed, 2016
Hafeez et al., 2016
Shabbir et al., 2016
Qadeer et al., 2016
Sattar et al., 2016
Ullah et al., 2016
Ikram et al., 2015
Riaz and Bashir, 2015
Sohail et al., 2015
Ashraf and Ahmed, 2015
Pesesky et al., 2015
Kathryn M. Day et al., 2013
Sultan et al., 2013
Saleem et al., 2013
Tanvir et al., 2012
Perry et al., 2011
Nazir et al., 2011
Ejaz et al., 2011
Ullah et al., 2009
Saghir et al., 2009

RE Model for Subgroup

(T² = 0.0018, df = 34, Q = 1307.62,
p < .0001; H² = 38.5, I² = 97.4%)

RE Model for All Studies

(T² = 0.0006, df = 45, Q = 2084.53,
p < .0001; H² = 46.3, I² = 97.8%)

Test for Subgroup Differences

(T² = 0.0005, df = 2, Q_M = 0.99,
p = 0.3799; H² = 33.9, I² = 97.1%)

Sample Trait–
Species Weight% Pr[95% CI]

H–TCH ESBL–EC 0.03% 0.73 [0.22, 1.23]
H–SIRS ESBL–En 1.90% 0.11 [0.06, 0.16]
H–TCH ESBL–En 2.51% 0.13 [0.09, 0.16]
H–UTI ESBL–EC 1.72% 0.03 [–0.03, 0.08]
H–TCH ESBL–EC 3.34% 0.01 [–0.01, 0.03]
H–TCH ESBL–EC 3.13% 0.01 [–0.01, 0.04]
H–TCH ESBL–KP 3.96% 0.00 [0.00, 0.01]
H–TCH ESBL–NTS 3.97% 0.00 [–0.00, 0.00]

0.01 [–0.02, 0.04]

H–Pe ACBL–KP 0.54% 0.44 [0.33, 0.56]
H–Pe ACBL–EC 3.53% 0.01 [–0.01, 0.02]
H–TCH ACBL–En 2.54% 0.01 [–0.02, 0.05]

0.13 [–0.46, 0.71]

H–ICU KP 0.07% 0.50 [0.15, 0.85]
H–TCH EC 0.21% 1.00 [0.80, 1.20]
H–TCH EC 1.81% 0.07 [0.02, 0.12]
H–UTI En 3.24% 0.03 [0.01, 0.06]
H–Pe En 0.22% 0.45 [0.26, 0.64]
H–Pe En 1.86% 0.11 [0.06, 0.16]
H–TCH NS–En 3.72% 0.04 [0.03, 0.05]
H–TCH EC 0.44% 0.33 [0.20, 0.46]
H–TCH KP 1.18% 0.14 [0.06, 0.21]
H–TCH En 1.26% 0.45 [0.38, 0.52]
H–UTI En 1.60% 0.39 [0.34, 0.45]
H–TCH En 3.08% 0.09 [0.07, 0.12]
H–S,B,T En 3.15% 0.01 [–0.02, 0.03]
H–UTI En 3.55% 0.03 [0.01, 0.04]
H–Pe En 3.35% 0.12 [0.10, 0.14]
H–TCH SE 2.56% 0.04 [0.00, 0.07]
H–ICU En 0.86% 0.21 [0.12, 0.29]
H–UTI En 0.90% 0.16 [0.07, 0.24]
H–ICU En 0.86% 0.29 [0.20, 0.38]
H–TCH En 0.58% 0.20 [0.09, 0.31]
H–Pe En 3.52% 0.07 [0.05, 0.08]
H–TCH SE 3.80% 0.00 [–0.01, 0.01]
H–CDS En 3.80% 0.02 [0.01, 0.03]
H–UTI En 3.22% 0.03 [0.01, 0.05]
H–TCH En 3.91% 0.08 [0.07, 0.08]
H–TCH En 0.46% 0.24 [0.11, 0.36]
H–TCH En 1.42% 0.19 [0.13, 0.25]
H–TCH En 3.95% 0.01 [0.01, 0.02]
H–Pe KP 0.88% 0.20 [0.12, 0.29]
H–CDS EC 3.76% 0.01 [–0.00, 0.02]
H–Hs,NHs NS–En 1.49% 0.18 [0.13, 0.24]
H–UTI En 2.74% 0.09 [0.05, 0.12]
H–Pe En 3.92% 0.01 [0.00, 0.01]
H–TCH KP 1.12% 0.13 [0.06, 0.20]
H–ACT En 0.32% 0.19 [0.04, 0.35]

0.11 [0.06, 0.16]

100.00% 0.07 [0.04, 0.10]

–0.5 0.0 0.5 1.0 1.5

Incidence Rate